HIV-associated opportunistic fungal infections: A guide to using the clinical microbiology laboratory

Southern African Journal of HIV Medicine

Volumn , Issue 28, 2007, Pages 18-23

  Govender, Nelesh ^a  

^a UNIVERSITY OF THE WITWATERSRAND   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; ANTIFUNGAL AGENT; ANTIRETROVIRUS AGENT; FLUCONAZOLE;

BLOOD CULTURE; CANDIDIASIS; CEREBROSPINAL FLUID ANALYSIS; CRYPTOCOCCOSIS; DERMATOMYCOSIS; ENDOSCOPY; FUNGUS CULTURE; FUNGUS IDENTIFICATION; HISTOPLASMOSIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; LUNG BIOPSY; LUNG LAVAGE; MICROSCOPY; MYCOSIS; ORAL BIOPSY; OROPHARYNX CANDIDIASIS; PATIENT MONITORING; PNEUMOCYSTIS PNEUMONIA; RECURRENCE RISK; REVIEW; SENSITIVITY AND SPECIFICITY; SKIN BIOPSY; SPOROTRICHOSIS; TRACHEOBRONCHIAL TOILET; URINALYSIS; VAGINA CANDIDIASIS;

EID: 38049093744     PISSN: 16089693     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (67)

1. Ampel NM. Emerging disease issues and fungal pathogens associated with HIV infection. Emerg Infect Dis 1966; 2: 109-116.
2. Holmes CB, Losina E, Walensky RP, Yazdanpanah Y, Freedberg KA. Review of human immunodeficiency virus type 1-related opportunistic infections in sub-Saharan Africa. Clin Infect Dis 2003; 36: 652-662.
3. Corbett EL, et al. Morbidity and mortality in South African gold miners: impact of untreated disease due to human immunodeficiency virus. Clin Infect Dis 2002; 34: 1251-1258.
4. Fisk DT, Meshnick S, Kazanjian PH. Pneumocystis carinii pneumonia in patients in the developing world who have acquired immunodeficiency syndrome. Clin Infect Dis 2003; 36: 70-78.
5. American Thoracic Society. Fungal infection in HIV-infected persons. Am J Respir Crit Care Med 1995; 152: 816-822.
6. Hage CA, Goldman M, Wheat LI. Mucosal and invasive fungal infections in HIV/AIDS. Eur J Med Res 2002; 7: 236-241.
7. Vazquez, JA, et al. Evolution of vaginal Candida species recovered from human immunodeficiency virus-infected women receiving fluconazole prophylaxis: the emergence of Candida glabrata? Terry Beirn Community Programs for Clinical Research in AIDS (CPCRA). Clin Infect Dis 1999; 28: 1025-1031.
8. NCCLS/CLSI. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts. 2002. 940 West Valley Road, Suite 400, Wayne, Pennsylvania, 19087-1898 USA, NCCLS/CLSI. NCCLS/CLSI document M27-A2.
9. Rex JH, et al. Practice guidelines for the treatment of candidiasis. Infectious Diseases Society of America. Clin Infect Dis 2000; 30: 662-678.
10. French N, et al. Cryptococcal infection in a cohort of HIV-1-infected Ugandan adults. AIDS 2002; 16: 1031-1038.
11. McCarthy KM, et al. Population-based surveillance for cryptococcosis in an antiretroviral-naive South African province with a high HIV seroprevalence. AIDS 2006; 20: 2199-2206.
12. Wong ML, Back P, Candy, G Nelson, G, Murray J. Cryptococcal pneumonia in African miners at autopsy. Int J Tuberc Lung Dis 2007; 11: 528-533.
13. Casadevall A, Perfect JR. Cryptococcus neoformans. In: Casadevall A, Perfect JR, eds. Washington, DC: American Society for Microbiology, 1998: 381-406.
14. Clark RA, Greer D, Atkinson W, Valainis GT, Hyslop N. Spectrum of Cryptococcus neoformans infection in 68 patients infected with human immunodeficiency virus. Rev Infect Dis 1990; 12: 768-777.
15. Gal AA, Evans S, Meyer PR. The clinical laboratory evaluation of cryptococcal infections in the acquired immunodeficiency syndrome. Diagn Microbiol Infect Dis 1987; 7: 249-254.
16. Tanner, DC, et al. Comparison of commercial kits for detection of cryptococcal antigen. J Clin Microbiol 1994; 32: 1680-1684.
17. Berlin L, Pincus JH. Cryptococcal meningitis. False-negative antigen test results and cultures in nonimmunosuppressed patients. Arch Neurol 1989; 46: 1312-1316.
18. Currie BP, Freundlich LF, Soto MA, Casadevall A. False-negative cerebrospinal fluid cryptococcal latex agglutination tests for patients with culture-positive cryptococcal meningitis. J Clin Microbiol 1993; 31: 2519-2522.
19. Sadamoto S, Ikeda R, Nishikawa A, Shinoda T. Evidence for interference by immune complexes in the serodiagnosis of cryptococcosis. Microbiol Immunol 1993; 37: 129-133.
20. Laurenson IF, Ross JD, Milne LJ. Microscopy and latex antigen negative cryptococcal meningitis. J Infect 1998; 36: 329-331.
21. To KK, Cheng VC, Tang BS, Fan YW, Yuen KY. False-negative cerebrospinal fluid cryptococcal antigen test due to small-colony variants of Cryptococcus neoformans meningitis in a patient with cystopleural shunt. Scand J Infect Dis 2006; 38: 1110-1114.
22. Kontoyiannis DP. What is the significance of an isolated positive cryptococcal antigen in the cerebrospinal fluid of cancer patients? Mycoses 2003; 46: 161-163.
23. Stoeckli TC, Burman WJ. Inactivated pronase as the cause of false-positive results of serum cryptococcal antigen tests. Clin Infect Dis 2001; 32: 836-837.
24. Millon L, Barale T, Julliot MC, Martinez J, Mantion G. Interference by hydroxyethyl starch used for vascular filling in latex agglutination test for cryptococcal antigen. J Clin Microbiol 1995; 33: 1917-1919.
25. Blevins LB, Fenn J, Segal H, Newcomb-Gayman P, Carroll KC. False-positive cryptococcal antigen latex agglutination caused by disinfectants and soaps. J Clin Microbiol 1995; 33: 1674-1675.
26. Ruchel R. False-positive reaction of a Cryptococcus antigen test owing to Pseudallescheria mycosis. Mycoses 1994; 37: 69.
27. Chanock SJ, Toltzis P, Wilson C. Cross-reactivity between Stomatococcus mucilaginosus and latex agglutination for cryptococcal antigen. Lancet 1993; 342: 1119-1120.
28. Sachs MK, Huang CM, Ost D, Jungkind DL Failure of dithiothreitol and pronase to reveal a false-positive cryptococcal antigen determination in cerebrospinal fluid. Am J Clin. Pathol 1991; 96: 381-384.
29. Heelan JS, Corpus L, Kessimian N. False-positive reactions in the latex agglutination test for Cryptococcus neoformans antigen. J Clin Microbiol 1991; 29: 1260-1261.
30. Boom WH, Piper DJ, Ruoff KL, Ferraro MJ. New cause for false-positive results with the cryptococcal antigen test by latex agglutination. J Clin Microbiol 1985; 22: 856-857.
31. Westerink MA, Amsterdam D, Petell RJ, Stram MN, Apicella MA. Septicemia due to DF-2. Cause of a false-positive cryptococcal latex agglutination result. Am J Med 1987; 83: 155-158.
32. Campbell, CK, Payne AL, Teall AJ, Brownell A, Mackenzie DW. Cryptococcal latex antigen test positive in patient with Trichosporon beigelii infection. Lancet 1995; 2: 43-44.
33. MacKinnon S, Kane JG, Parker RH. False-positive cryptococcal antigen test and cervical prevertebral abscess. JAMA 1978; 240: 1982-1983.
34. Micol R, et al. Prevalence, determinants of positivity, and clinical utility of cryptococcal antigenemia in Cambodian HIV-infected patients. J Acquir Immune Defic Syndr 2007; 45: 555-559.
35. McCarthy K, et al. Guidelines for the diagnosis, management and prevention of cryptococcal meningitis and disseminated cryptococcosis in HIV-infected patients. Southern African Journal of HIV Medicine (2007).
36. Saag MS, et al. Comparison of amphotericin B with fluconazole in the treatment of acute AIDS-associated cryptococcal meningitis. The NIAID Mycoses Study Group and the AIDS Clinical Trials Group. N Engl J Med 1992; 326: 83-89.
37. Brouwer AE, et al. Combination antifungal therapies for HIV-associated cryptococcal meningitis: a randomised trial. Lancet 2004; 363: 1764-1767.
38. Feldmesser M, Harris C, Reichberg S, Khan S, Casadevall A. Serum cryptococcal antigen in patients with AIDS. Clin Infect Dis 1996; 23: 827-830.
39. Desmet P, Kayembe KD, De VC. The value of cryptococcal serum antigen screening among HIV-positive/AIDS patients in Kinshasa, Zaire. AIDS 1989; 3: 77-78.
40. Tassie JM, et al. Systematic screening of cryptococcal antigenemia in HIV-positive adults in Uganda. J Acquir Immune Defic Syndr 2003; 33: 411-412.
41. Hoffmann S, Stenderup J, Mathiesen LR. Low yield of screening for cryptococcal antigen by latex agglutination assay on serum and cerebrospinal fluid from Danish patients with AIDS or ARC. Scand J Infect Dis 1991; 23: 697-702.
42. Nelson MR et al. The value of serum cryptococcal antigen in the diagnosis of cryptococcal infection in patients infected with the human immunodeficiency virus. J Infect 1990; 21: 175-181.
43. Powderly WG, Cloud GA, Dismukes WE, Saag MS. Measurement of cryptococcal antigen in serum and cerebrospinal fluid: value in the management of AIDS-associated cryptococcal meningitis. Clin Infect Dis 1994; 18: 789-792.
44. Antinori S, et al. The role of cryptococcal antigen assay in diagnosis and monitoring of cryptococcal meningitis. J Clin Microbiol 2005; 43: 5828-5829.
45. Aberg JA, Watson J, Segal M, Chang LW. Clinical utility of monitoring serum cryptococcal antigen (sCRAG) titers in patients with AIDS-related cryptococcal disease.HIV Clin Trials 2000; 1: 1-6.
46. Manfredi R, Calza L, Chiodo F. AIDS-associated Cryptococcus infection before and after the highly active antiretroviral therapy era: emerging management problems. Int J Antimicrob Agents 2003; 22: 449-452.
47. Mussini C, et al. Discontinuation of maintenance therapy for cryptococcal meningitis in patients with AIDS treated with highly active antiretroviral therapy: an international observational study. Clin Infect Dis 2004; 38: 565-571.
48. Lortholary O, et al. Incidence and risk factors of immune reconstitution inflammatory syndrome complicating HIV-associated cryptococcosis in France. AIDS 2005; 19: 1043-1049.
49. Aller AI, et al. Comparison of the Etest and microdilution method for antifungal susceptibility testing of Cryptococcus neoformans to four antifungal agents. J Antimicrob Chemother 2000; 46: 997-1000.
50. Aller AI, et al. Correlation of fluconazole MICs with clinical outcome in cryptococcal infection. Antimicrob Agents Chemother 2000; 44: 1544-1548.
51. Dannaoui E, et al. Results obtained with various antifungal susceptibility testing methods do not predict early clinical outcome in patients with cryptococcosis. Antimicrob Agents Chemother 2006; 50: 2464-2470.
52. Pfaller MA, et al. Global trends in the antifungal susceptibility of Cryptococcus neoformans (1990 to 2004). J Clin Microbiol 2005; 43: 2163-2167.
53. Jung AC, Paauw DS. Diagnosing HIV-related disease: using the CD4 count as a guide. J Gen Intern Med 1998; 13: 131-136.
54. Thomas CF Jr, Limper AH. Pneumocystis pneumonia. N Engl J Med 2004; 350: 2487-2498.
55. Mathis A, Weber R, Kuster H, Speich R. Simplified sample processing combined with a sensitive one-tube nested PCR assay for detection of Pneumocystis carinii in respiratory specimens. J Clin Microbiol 1997; 35: 1691-1695.
56. Turner D, Schwarz Y, Yust I. Induced sputum for diagnosing Pneumocystis carinii pneumonia in HIV patients: new data, new issues. Eur Respir J 2003; 21: 204-208.
57. Takahashi T, et al. Pneumocystis carinii carriage in immunocompromised patients with and without human immunodeficiency virus infection. J Med Microbiol 2002; 61: 611-614.
58. Dini L, et al. Prevalence of DHPS polymorphisms associated with sulfa resistance in South African Pneumocystis jirovecii strains. J Eukoryot Microbiol 2006; 53: Suppl 1: S110-6111.
59. Centers for Disease Control, 1993 Revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Morbid Mortal Wkly Rep 1992; 41.
60. Gugnani HC, Muotoe-Okafor F. African histoplasmosis: a review. Rev Iberoam Micol 1997; 14: 155-159.
61. Greene L, Peters B, Lucas SB, Pozniak AL. Extrapulmonary tuberculosis masking disseminated histoplasmosis in AIDS. Sex Transm Infect 2000; 76: 54-56.
62. Kauffman CA. Histoplasmosis: a clinical and laboratory update. Clin Microbiol Rev 2007; 20: 115-132.
63. Vetter E, et al. Comparison of the BACTEC MYCO/F Lytic bottle to the isolator tube, BACTEC Plus Aerobic F/bottle, and BACTEC Anaerobic Lytic/10 bottle and comparison of the BACTEC Plus Aerobic F/bottle to the Isolator tube for recovery of bacteria, mycobacteria, and fungi from blood. J Clin Microbiol 2001; 39: 4380-4386.
64. Wheat LJ. Improvements in diagnosis of histoplasmosis. Expert Opin Biol Ther 2006; 6: 1207-1221.
65. Dupont B, et al. Mycoses in AIDS. Med Mycol 2000; 38: Suppl 1, 259-267.
66. Marques SA, et al. Mycoses associated with AIDS in the Third World. Med Mycol 2000; 38: Suppl 1, 269-279.
67. Rex JH, et al. Antifungal susceptibility testing: practical aspects and current challenges. Clin Microbiol Rev 2001; 14: 643-658.